Needham & Company
-
Notable Analyst Rating Changes 04/16: (SFUN) (TWTR) (YELP) Upgraded; (INTC) (UNH) (GDP) Downgraded
-
Streetinsider.com's Hot Lunchtime Reads 07/25: (NFLX) (AAPL) (ALTR) (REGN) (AMRN) (INFN)
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Priority, Shmyriority - 90 More Days to Prepare for Launch - Remain Positively Inclined
-
Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Upcoming August Event May Signal August Opportunities
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Summer Solstice & Extra Daylight for AMD Patients with a New Potential Treatment Option
-
Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Raising PT
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); VELOUR...Looking Good! Positive Phase 3 Results in CRC Add Another Major Disease Category
-
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
-
Needham & Company Maintains a 'Buy' on Regeneron Pharma (REGN); Failed Aflibercept Trial in 2nd-line Lung Cancer Doesn’t Change Our Thesis
-
Needham & Company maintains a 'Buy' on Regeneron Pharma (REGN); Believe 2011 Will Build on Successes of 2010
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Angiogenesis Mtg Highlights Robust Full Dataset for Multiple VEGF Trap-Eye Trials
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharma (REGN); Positioned for Transformational Year
-
Needham & Company Reiterates a 'Buy' Rating on Regeneron Pharma (REGN)
-
Needham & Company Reiterates a 'Buy' Rating on Regeneron Pharmaceuticals (REGN); Multiple Catalysts in 2H10 to Potentially Drive the Stock Valuation
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharmaceuticals (REGN); Investor Day Review – Have More Confidence in the Clinical Trial and Commercialization in Gout
-
Needham & Company Reiterates a 'Buy' on Regeneron Pharmaceuticals (REGN); Preview Shows Progress in Both Late-Stage Programs
-
Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)